ALCEDIAG
Description
ALCEDIAG is at the forefront of advancing mental health diagnostics through the development and introduction into clinical routine of blood tests, monitoring solutions and companion tests.
More specifically, ALCEDIAG has successfully developed the myEDIT-B blood test. CE marked and clinically validated with excellent performance (>80%), myEDIT-B is the first biological tool to aid in the differential diagnosis of depression and bipolar disorders. Designed for clinicians, the test complements existing clinical assessments. Its primary goal is to empower clinicians to facilitate the prompt selection of appropriate therapeutic treatments and to aid patients in leading improved lives by shortening the typical delays associated with diagnosis, which is over 8 years currently. On medical prescription, myEDIT-B is indicated for adult patients in a moderate or severe depressive phase who are being treated for that depression at the time of the test. For the patient, it requires a simple blood test.
Technically, myEDIT-B is based on RNA-edited blood biomarkers, using the next-generation sequencing technique (NGS), coupled with an artificial intelligence algorithm.
The myEDIT-B test has been available in France since April 2024, and is distributed by SYNLAB laboratories.
